Several studies have been conducted in tumor models showing that the anti-tumoral effect of dasatinib involves CD8 T-cells, as increased levels of circulating tumor antigen-specific CD8 T-cells and a higher number of tumor-infiltrating CD8 T-cells have been observed10,39,40. This evidence concerns the gene CD8A and neoplasm.